From L-R: EPFL professor Christian Heinis, Novo Holdings principal João Ribas and partner Morten Døssing
February 29, 2024 06:30 AM EST
Financing
Startups

No­vo Hold­ings in­vests in macro­cy­cle start­up Or­bis as once-over­looked mol­e­cules get new in­ter­est

Lei Lei Wu

News Reporter

At long last, macro­cy­cles are spin­ning in­to the spot­light.

On Thurs­day, Or­bis Med­i­cines launched with €26 mil­lion in seed fund­ing from Eu­ro­pean VC fund For­bion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times